BIO BIOB · Bio-Rad Laboratories, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $592.10M | - | $653.00M | $651.60M | $585.40M | - | $649.73M | $638.48M | $610.82M | - |
| Cost of Revenue | $282.70M | - | $309.60M | $306.30M | $279.40M | - | $293.83M | $283.36M | $284.85M | - |
| Gross Profit | $309.40M | - | $343.40M | $345.30M | $306.00M | - | $355.90M | $355.12M | $325.97M | - |
| R&D | $62.90M | - | $71.30M | $60.50M | $73.50M | - | $91.00M | $58.90M | $66.38M | - |
| SG&A | $212.40M | - | $206.80M | $207.70M | $208.80M | - | $200.44M | $194.72M | $214.88M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $34.10M | - | $65.30M | $77.10M | $23.70M | - | $64.47M | $101.50M | $44.71M | - |
| Interest Expense | $12.30M | - | $12.30M | $12.60M | $12.00M | - | $12.17M | $12.26M | $12.28M | - |
| Income Tax | ($162.70M) | - | ($89.20M) | $96.20M | $19.40M | - | $208.45M | ($620.79M) | $107.16M | - |
| Net Income | ($527.10M) | - | ($341.90M) | $317.80M | $64.00M | - | $653.17M | ($2.17B) | $383.92M | - |
| EPS - Basic | ($19.55) | - | ($12.70) | $11.67 | $2.29 | - | $23.37 | ($76.26) | $13.46 | - |
| EPS - Diluted | ($19.55) | - | ($12.70) | $11.67 | $2.29 | - | $23.34 | ($76.26) | $13.45 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $507.20M | $529.80M | $395.80M | $369.30M | $521.40M | $488.10M | $410.38M | $406.91M | $433.28M | $403.81M |
| Accounts Receivable | $426.20M | $460.60M | $464.70M | $469.90M | $424.70M | $452.50M | $461.94M | $445.51M | $444.81M | $489.02M |
| Inventory | $770.50M | $740.70M | $783.20M | $798.80M | $790.10M | $760.00M | $804.28M | $803.69M | $783.37M | $780.52M |
| Accounts Payable | $133.10M | $129.00M | $128.80M | $139.30M | $137.90M | $122.30M | $122.19M | $126.69M | $102.75M | $144.63M |
| Current Assets | $2.94B | $2.91B | $2.84B | $2.81B | $3.04B | $3.03B | $3.06B | $3.06B | $3.06B | $3.05B |
| Total Assets | $9.79B | $10.58B | $9.70B | $10.21B | $9.53B | $9.36B | $10.60B | $9.69B | $12.61B | $12.30B |
| Current Liabilities | $917.00M | $517.00M | $522.30M | $548.90M | $506.60M | $467.80M | $497.94M | $486.96M | $466.15M | $522.80M |
| Long-term Debt | $802.90M | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B |
| Total Liabilities | $2.94B | $3.12B | $2.96B | $3.09B | $2.85B | $2.79B | $3.12B | $2.91B | $3.56B | $3.56B |
| Stockholders' Equity | $6.85B | $7.45B | $6.74B | $7.13B | $6.68B | $6.57B | $7.49B | $6.78B | $9.05B | $8.74B |
| Retained Earnings | $7.65B | $8.18B | $7.46B | $7.80B | $7.48B | $7.42B | $8.13B | $7.48B | $9.64B | $9.26B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $108.10M | - | - | - | $129.90M | - | - | - | $69.79M | - |
| Investing Cash Flow | ($93.20M) | - | - | - | $2.90M | - | - | - | ($43.09M) | - |
| Financing Cash Flow | ($44.00M) | - | - | - | ($97.70M) | - | - | - | $21.0K | - |
| CapEx | $30.00M | - | - | - | $34.40M | - | - | - | $40.18M | - |
| Free Cash Flow | $78.10M | - | - | - | $95.50M | - | - | - | $29.62M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 52.3% | - | 52.6% | 53.0% | 52.3% | - | 54.8% | 55.6% | 53.4% | - |
| Operating margin | 5.8% | - | 10.0% | 11.8% | 4.0% | - | 9.9% | 15.9% | 7.3% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -89.0% | - | -52.4% | 48.8% | 10.9% | - | 100.5% | -339.2% | 62.9% | - |
| Free cash flow margin | 13.2% | - | - | - | 16.3% | - | - | - | 4.8% | - |
| FCF / Net income | -0.15 | - | - | - | 1.49 | - | - | - | 0.08 | - |
| R&D / Revenue | 10.6% | - | 10.9% | 9.3% | 12.6% | - | 14.0% | 9.2% | 10.9% | - |
| SG&A / Revenue | 35.9% | - | 31.7% | 31.9% | 35.7% | - | 30.8% | 30.5% | 35.2% | - |
| Effective tax rate | - | - | - | 23.2% | 23.3% | - | 24.2% | - | 21.8% | - |
| Return on assets | -5.4% | - | -3.5% | 3.1% | 0.7% | - | 6.2% | -22.4% | 3.0% | - |
| Return on equity | -7.7% | - | -5.1% | 4.5% | 1.0% | - | 8.7% | -31.9% | 4.2% | - |
| Return on invested capital | 0.4% | - | 0.6% | 0.7% | 0.2% | - | 0.6% | 1.0% | 0.3% | - |
| Liquidity | ||||||||||
| Current ratio | 3.21 | 5.62 | 5.44 | 5.12 | 5.99 | 6.48 | 6.14 | 6.28 | 6.57 | 5.83 |
| Quick ratio | 2.37 | 4.19 | 3.94 | 3.67 | 4.43 | 4.85 | 4.52 | 4.63 | 4.89 | 4.34 |
| Cash ratio | 0.55 | 1.02 | 0.76 | 0.67 | 1.03 | 1.04 | 0.82 | 0.84 | 0.93 | 0.77 |
| Leverage | ||||||||||
| Debt / Equity | 0.12 | 0.16 | 0.18 | 0.17 | 0.18 | 0.18 | 0.16 | 0.18 | 0.13 | 0.14 |
| Debt / Assets | 0.08 | 0.11 | 0.12 | 0.12 | 0.13 | 0.13 | 0.11 | 0.12 | 0.10 | 0.10 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 2.8x | - | 5.3x | 6.1x | 2.0x | - | 5.3x | 8.3x | 3.6x | - |
| Equity multiplier | 1.43 | 1.42 | 1.44 | 1.43 | 1.43 | 1.43 | 1.42 | 1.43 | 1.39 | 1.41 |
| Liabilities / Assets | 0.30 | 0.30 | 0.31 | 0.30 | 0.30 | 0.30 | 0.29 | 0.30 | 0.28 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.06 | - | 0.07 | 0.06 | 0.06 | - | 0.06 | 0.07 | 0.05 | - |
| Inventory turnover | 0.37 | - | 0.40 | 0.38 | 0.35 | - | 0.37 | 0.35 | 0.36 | - |
| Days sales outstanding | 263d | - | 260d | 263d | 265d | - | 260d | 255d | 266d | - |
| Days inventory outstanding | 995d | - | 923d | 952d | 1032d | - | 999d | 1035d | 1004d | - |
| Days payable outstanding | 172d | - | 152d | 166d | 180d | - | 152d | 163d | 132d | - |
| Cash conversion cycle | 1086d | - | 1031d | 1049d | 1117d | - | 1107d | 1127d | 1138d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1.1% | - | 0.5% | 2.1% | -4.2% | - | 2.8% | -6.3% | -9.8% | - |
| Revenue CAGR (3y) | -4.4% | - | -1.4% | -1.9% | -5.8% | - | -4.5% | -3.7% | -5.6% | - |
| Revenue CAGR (5y) | -4.0% | - | 0.2% | 3.9% | 0.5% | - | 3.0% | 2.2% | 2.0% | - |
| Gross profit growth (YoY) | 1.1% | - | -3.5% | -2.8% | -6.1% | - | 6.0% | -2.0% | -10.1% | - |
| Operating income growth (YoY) | 43.9% | - | 1.3% | -24.0% | -47.0% | - | -29.1% | 13.3% | -27.8% | - |
| Net income growth (YoY) | - | - | - | - | -83.3% | - | 514.7% | -86.3% | 456.7% | - |
| EPS growth (YoY) | - | - | - | - | -83.0% | - | 541.2% | - | 479.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | -43.6% | - | -25.4% | - |
| EPS CAGR (5y) | - | - | - | -18.3% | -36.8% | - | - | - | -14.1% | - |
| FCF growth (YoY) | -18.2% | - | - | - | 222.5% | - | - | - | -52.5% | - |
| FCF CAGR (5y) | -3.7% | - | - | - | 18.3% | - | - | - | 8.9% | - |
| Book value growth (YoY) | 2.6% | 13.5% | -10.0% | 5.2% | -26.2% | -24.8% | -11.0% | -19.7% | -7.3% | -9.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$2.58B totalUS$1.02B · 39.6%
Europe$881.80M · 34.1%
Asia Pacific$513.30M · 19.9%
Americas$165.40M · 6.4%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing BIO-RAD LABORATORIES against the 5 most active filers in the same SIC group.